Lisata Therapeutics Inc (LSTA)

10:20 AM

Neostem stock plunges to 52-week low at $2.01 amid market challenges - Investing.com India

10:20 AM

Mar 08, 2025

Lisata Therapeutics CEO discusses AI drug discovery collaborationICYMI - Proactive Investors

Mar 08, 2025

Mar 07, 2025

Lisata Therapeutics expands drug discovery with GATC AI collaboration - Proactive Investors USA

Mar 07, 2025

Mar 06, 2025

Lisata Therapeutics to Present at the Investival Showcase USA - The Manila Times

Mar 06, 2025

Mar 06, 2025

Can This Clinical-Stage Pharma Company Transform Solid Tumor Treatment? CEO Presents Next Month - StockTitan

Mar 06, 2025

Mar 05, 2025

Lisata Therapeutics and GATC Health Consummate First Step - GlobeNewswire

Mar 05, 2025

Mar 05, 2025

Market movers: General Motors, Moderna, CrowdStrike, Lisata... - Proactive Investors UK

Mar 05, 2025

Mar 05, 2025

Lisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI Technology - Nasdaq

Mar 05, 2025

Mar 05, 2025

Lisata Therapeutics partners with GATC Health to advance AI-driven drug development - Proactive Investors UK

Mar 05, 2025

Mar 05, 2025

Can AI Revolutionize Lisata's Pancreatic Cancer Drug? New GATC Health Partnership Aims to Prove It - StockTitan

Mar 05, 2025

Mar 05, 2025

Neostem stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia

Mar 05, 2025

Mar 03, 2025

Neostem stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025

Feb 28, 2025

Lisata Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Feb 28, 2025

Feb 28, 2025

Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid Financial Challenges - GuruFocus.com

Feb 28, 2025

Feb 28, 2025

Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... - Yahoo Finance Australia

Feb 28, 2025

Feb 28, 2025

Lisata Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Feb 28, 2025

Feb 27, 2025

Earnings call transcript: Lisata Therapeutics Q4 2024 sees steady progress By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 27, 2025

Lisata Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025

Feb 27, 2025

Earnings call transcript: Lisata Therapeutics Q4 2024 sees steady progress - Investing.com India

Feb 27, 2025

Feb 27, 2025

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

Feb 27, 2025

Lisata Therapeutics CEO: 2025 to be ‘data-rich’ as certepetide trials progress - Proactive Investors UK

Feb 27, 2025

Feb 27, 2025

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Can Lisata's Promising Pancreatic Cancer Treatment Offset Its $20M Annual Losses? - StockTitan

Feb 27, 2025

Feb 25, 2025

Lisata Therapeutics Inc expected to post a loss of 76 cents a shareEarnings Preview - TradingView

Feb 25, 2025

Feb 25, 2025

Endometriosis Pipeline Drugs Analysis Report: FDA Approvals, - openPR.com

Feb 25, 2025

Feb 22, 2025

Lisata Therapeutics (LSTA) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 22, 2025

Feb 20, 2025

LSTALisata Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 20, 2025

Feb 20, 2025

Lisata Therapeutics to Report Full Year 2024 Financial - GlobeNewswire

Feb 20, 2025

Feb 20, 2025

Lisata Therapeutics Earnings Call: 2024 Results and Corporate Update on Feb 27 - StockTitan

Feb 20, 2025

Feb 20, 2025

Lisata Therapeutics to Report 2024 Financial Results and Host Conference Call on February 27, 2025 - Nasdaq

Feb 20, 2025

Feb 17, 2025

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Sees Significant Decline in Short Interest - Defense World

Feb 17, 2025

Feb 16, 2025

Lisata reports positive early trial results for pancreatic cancer drug - MSN

Feb 16, 2025

Feb 11, 2025

Refractory Angina Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Gene Biotherapeutics, XyloCor Therapeutics, Centocor, Lisata Therapeutics - The Globe and Mail

Feb 11, 2025

Feb 07, 2025

Lisata Therapeutics (NASDAQ:LSTA) Trading Up 0.8% – Here’s What Happened - Defense World

Feb 07, 2025

Feb 06, 2025

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire

Feb 06, 2025

Feb 05, 2025

Lisata Therapeutics CEO to present at 2025 BIO CEO & Investor Conference - Proactive Investors USA

Feb 05, 2025

Feb 05, 2025

Lisata's Cancer Treatment Pipeline Takes Center Stage at Major Biotech Investor Conference - StockTitan

Feb 05, 2025

Jan 29, 2025

Lisata completes subject enrolment in multi-cancer trial of certepetide - MSN

Jan 29, 2025

Jan 26, 2025

Lisata falls after mid-stage data for anticancer agent - MSN

Jan 26, 2025

Jan 25, 2025

Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMI - Proactive Investors UK

Jan 25, 2025

Jan 24, 2025

Lisata reports positive early trial results for pancreatic cancer drug By Investing.com - Investing.com Australia

Jan 24, 2025

Jan 23, 2025

Lisata Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA Trial Results - Proactive Investors USA

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results - Proactive Investors USA

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics and WARPNINE Announce Encouraging - GlobeNewswire

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial - Proactive Investors USA

Jan 23, 2025